Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses

• Published in: ACS nano Vol. 18; no. 17; pp. 11200 - 11216
• Main Authors: Fu, Wenjiao, Guo, Mengyu, Zhou, Xuemei, Wang, Zhenzhen, Sun, Jiufeng, An, Yaling, Guan, Tong, Hu, Mingdi, Li, Jiayang, Chen, Ziwei, Ye, Jinmin, Gao, Xingfa, Gao, George Fu, Dai, Lianpan, Wang, Yaling, Chen, Chunying
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 30.04.2024
• Subjects: self-assembly; strain-dependent sol−gel transition; self-healing hydrogels; intranasal vaccines; mucosal immunity
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.4c00155

Intranasal vaccines, eliciting mucosal immune responses, can prevent early invasion, replication, and transmission of pathogens in the respiratory tract. However, the effective delivery of antigens through the nasal barrier and boosting of a robust systematic and mucosal immune remain challenges in intranasal vaccine development. Here, we describe an intranasally administered self-healing hydrogel vaccine with a reversible strain-dependent sol–gel transition by precisely modulating the self-assembly processes between the natural drug rhein and aluminum ions. The highly bioadhesive hydrogel vaccine enhances antigen stability and prolongs residence time in the nasal cavity and lungs by confining the antigen to the surface of the nasal mucosa, acting as a “mucosal mask”. The hydrogel also stimulates superior immunoenhancing properties, including antigen internalization, cross-presentation, and dendritic cell maturation. Furthermore, the formulation recruits immunocytes to the nasal mucosa and nasal-associated lymphoid tissue (NALT) while enhancing antigen-specific humoral, cellular, and mucosal immune responses. Our findings present a promising strategy for preparing intranasal vaccines for infectious diseases or cancer.